The FDA has approved ReShape Integrated Dual Balloon System, the first non-surgical weight loss procedure for people with mild-to-moderate obesity.
The FDA has approved Orkambi (lumacaftor/ivacaftor; Vertex), the first and only drug indicated for the treatment of cystic fibrosis (CF) in patients aged ≥12 who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Researchers from the Washington University School of Medicine in St. Louis, MO, studied data from the National Health and Nutrition Examination Survey from 2007–2012 to estimate the prevalence of overweight and obesity.
Excessive eating may be due to a bad night's sleep, a study published in the Journal of Health Psychology has proposed.
For obese Americans who are deficient in vitamin D, taking a supplement of the nutrient might help them lose weight, new research suggests.
Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of ≥30kg/m2 (obese) or ≥27kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia).
A specific drug class for the treatment of type 2 diabetes has been linked to an increased risk of weight gain, and researchers have new clues as to how these medications may activate sensors in the brain that lead to increased hunger.
Thiamin (vitamin B1) deficiency was found in up to one-third of obese patients seeking bariatric surgery, according to data from a large-scale study.